Centerwatch.com produced an interesting article on the implementation of new strategies to improve drug developer’s access to comparator drugs for clinical testing. The article brings to light the difficulty of obtaining comparator drugs, with the Tufts Center for study of Drug Development Director calling it a formidable challenge. This has led to drug providers embracing a proactive approach on getting the drugs they need. They are able to accomplish this by improving communication between R&D and investing in comparator supply companies to make sure in-house capabilities are up to snuff. To read the complete article click here.
Single IRB – A Guide to the Common Rule sIRB Mandate
The sIRB requirement is active. Is your study affected?
Clinical Research Accelerated
You need high quality, timely board reviews so that you can get your study in the clinic.
Recent Posts
Pearl IRB 2024 Year-End Schedule
Snowball Sampling: Is it ethical to pay your study subjects to recruit participants on your behalf?
Improving Exempt Submissions: 7 Tips to Reduce Revision Requests
Common Rule Exceptions to the Use of a Single IRB for Multi-site Research Ends After May 11, 2023
Pearl IRB 2022 Year-End Schedule